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Abstract
Introduction: Hepatic and splenic hemangiomas are common benign tumors that mainly affect
female patients. Giant splenic hemangiomas are extremely rare, especially when correlated with
multiple hepatic hemangiomas. Pathogenetic mechanisms between hemangiomas and oral
contraceptives, as well as therapeutic approaches, are analyzed in this case report, in particular for
the management of synchronous splenic and hepatic hemangiomas.
Case presentation: We report here a 42-year-old woman with a giant splenic hemangioma,
multiple hepatic hemangiomas and a history of oral estrogen intake for many years. At first it was
difficult to determine the organ from which the giant hemangioma originated. Angiography proved
extremely helpful in tracing its origin in the spleen. Hematomas in the giant hemangioma posed a
significant threat of rupture and catastrophic hemorrhage. We left the small hepatic hemangiomas
in place, and removed the spleen along with the giant splenic hemangioma.
Conclusion: Diagnostic pitfalls in the determination of the origin of this giant hemangioma,
attribution of its origin to the spleen angiographically, the unusual co-existence of the giant splenic
hemangioma with multiple hepatic ones, and the potential threat of rupture of the giant
hemangioma are some of the highlights of this case report. Estrogen administration represents a
pathogenic factor that has been associated with hemangiomas in solid organs of the abdominal
cavity. The therapeutic dilemma between resection and embolization of giant hemangiomas is
another point of discussion in this case report. Splenectomy for the giant splenic hemangioma
eliminates the risk of rupture and malignant degeneration, whereas observation for the small
hepatic ones (<4 cm) was the preferable therapeutic strategy in our patient.
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Introduction
Splenic hemangioma is a vascular malformation that rep-
resents the most common benign primary neoplasm of
the spleen. Its prevalence at autopsy ranges from 0.03% to
14% and it is the hemangioma most commonly seen in
adults in the mid-30- to mid-50-year-old range [1].
Most hemangiomas are small asymptomatic lesions that
are found incidentally. Previous studies have noted liver
and spleen hemangioma augmentation during estrogen
administration for endometriosis treatment, revealing a
potential association [2]. Additionally the co-existence of
benign hepatic and giant splenic hemangiomas is
extremely rare. To our knowledge this is the first biblio-
graphic case report of this combination.
Case presentation
A 42-year-old woman presented with a left upper abdom-
inal distention, early satiety and discomfort. There was no
family history of hematological or splenic disorders.
There was no evidence of thrombocytopenia, hemor-
rhagic episodes, hepatomegaly or lymphadenopathy. The
patient had received estrogen therapy as treatment for
endometriosis for 10 years, but she discontinued this
medication 12 years prior to her presentation to our unit.
The patient had a palpable mass in her left upper abdo-
men. The mass could be palpated approximately 9 cm
below the left costal margin. Her full blood count was in
the normal range.
Initially a spiral computed tomography (CT) scan with IV
contrast showed multiple hypodense lesions with centrip-
etal filling in delayed venous phase compatible with
hemangiomas. Two large lesions were located in the right
hepatic lobe and multiple smaller ones in the caudate and
left lobe. All these hepatic lesions were consistent with the
features of hemangiomas.
The CT scan also showed a large hemangioma-like forma-
tion in the left abdomen. It was difficult to determine
whether this originated from the spleen or from the left
adrenal gland, and a large cyst of the right ovary, suspi-
cious of endometriosis (Figure 1), was also observed. The
MRI scan, undertaken subsequently, was no more helpful
and also raised the suspicion of an adrenal tumor.
Selective arteriography of renal arteries, SMA (superior
mesenteric artery), and the celiac trunk, undertaken to
clarify the vascularity of the lesion, showed a giant splenic
hemangioma with its vascular supply deriving from the
splenic artery (Figure 2).
We decided to proceed to splenectomy because of the pos-
sibility of malignant transformation and of rupture and
massive bleeding, complications which have been
reported by other authors [1,3,4]. The patient underwent
elective splenectomy and right ovarectomy. The spleen
was 20 cm at its largest dimension, with areas of rupture
and creation of local central hematomas (Figure 3). Pre-
splenectomy vaccination was administered 2 weeks prior
to surgery.
Histology of the spleen showed a large hemangioma with
central foci of hematoma (Figure 3). At the periphery of
the hematoma and inside the splenic parenchyma, there
were many blood-filled spaces surrounded by dilated ves-
sels (Figure 3). The internal surface of the ovarian cyst was
lined with cylindrical endometrial epithelium and with
endometrial stroma and occasional endometrial glands
underneath. The histological findings confirmed the diag-
nosis of a cavernous hemangioma with hemorrhage and
hematoma formation and of an ovarian cyst with
endometriosis. The postoperative course was uneventful
and 1 year after surgery the patient has remained symp-
tom free.
Discussion
The first successful surgery for splenic hemangioma was
reported by Hodge in 1895. Hemangiomas constitute the
majority of benign hepatic neoplasms and are nine times
more frequent in females than in males [1]. Arising from
sinusoidal epithelium, splenic hemangiomas are thought
to be congenital in origin. Most cases are sporadic; how-
ever, occasionally they are inherited in autosomal domi-
Computed tomography appearance of giant splenic hemangi- oma and liver hemangiomatosis Figure 1
Computed tomography appearance of giant splenic 
hemangioma and liver hemangiomatosis. Cavernous 
hemangioma of the spleen and multiple hepatic cavernous 
hemangiomas displayed in a computed tomography 
hypodense image after IV contrast injection and peripheral, 
centripetal enhancement.Journal of Medical Case Reports 2008, 2:147 http://www.jmedicalcasereports.com/content/2/1/147
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nant fashion with moderate to high rates of penetrance
[5].
Hemangiomas are often asymptomatic and undergo
enlargement in fewer than 10% of cases, manifesting as a
palpable non-tender mass in the left upper quadrant. Very
rarely, splenic hemangiomas may become as large as 25
cm [4]. Generalized splenomegaly may be present, but
blood tests are often normal. Splenic hemangioma may
occur as part of generalized angiomatosis, as seen in Klip-
pel-Trenaunay syndrome or Kasabach-Meritt syndrome
[6,7]. There was no clinical or laboratory evidence associ-
ating either syndrome to our case. Nevertheless there are
some reports in the literature that describe the synchro-
nous presence of liver and spleen hemangioma [8].
CT and MRI failed to achieve appreciable sensitivity and
specificity to define the origin of the giant splenic heman-
gioma we describe. Velkova and Neveda report a com-
bined sensitivity of 61.3% for ultrasound and CT scan in
the recognition of liver and spleen hemangiomas, leaving
a substantial number of cases requiring further investiga-
tive procedures [9]. They also emphasize the importance
of digital angiography in the accurate diagnosis of heman-
giomas. Tarazov et al. [8] and Yamamoto et al. [4] high-
light the efficacy of angiography and arterial embolism in
the diagnosis and treatment of hemangiomas. The MRI
appearance of splenic hemangiomas has been described
as being similar to that of hepatic hemangiomas. How-
ever, larger hemangiomas may have a variable MRI pat-
tern because of complicating features such as hemorrhage,
infarction and thrombosis. Differentiation of a splenic
hemangioma from malignancy may not be feasible solely
on the basis of MRI. The 99T cm-labeled erythrocyte scin-
tigraphy scan is a useful diagnostic modality for large
splenic hemangiomas. Recently the employment of single
photon emission computed tomography scanning has
enhanced the diagnostic sensitivity of scintigraphy to 90%
[10]. An alternative preoperative diagnostic intervention
is percutaneous needle biopsy under sonographic guid-
ance, which provides scarce material for histological
examination and should not be employed because of the
high risk of hemorrhage [10].
The presence of central hematomas in the giant hemangi-
oma we describe showed possible rupture. Serious com-
plications of hemangiomas include rupture and
malignant transformation. Spontaneous rupture of a giant
hepatic hemangioma (diameter >4 cm) with hemoperito-
neum occurs very rarely. Willcox et al. report a spontane-
ous rupture incidence of 25% [1]. Malignant
transformation has been reported to occur more fre-
quently with large or multiple hemangiomas and leads
most surgeons to favor splenectomy [1,10]. The latter is
considered to be a radical treatment for splenic hemangi-
oma.
Splenectomy may be efficacious in the correction of coag-
ulation abnormalities in Kassabach-Meritt syndrome
associated with ruptured giant splenic hemangiomas
[6,7]. An alternative approach is partial splenectomy,
Pathology highlighted results Figure 3
Pathology highlighted results. Cavernous splenic heman-
gioma: multiple blood-filled spaces (lakes), with flat endothe-
lial cells and areas of hematoma.
Angiographic appearance of cavernous splenic hemangioma Figure 2
Angiographic appearance of cavernous splenic 
hemangioma. 1. Splenic artery (black arrows). 2. Celiac 
trunk (white arrow).Journal of Medical Case Reports 2008, 2:147 http://www.jmedicalcasereports.com/content/2/1/147
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especially in childhood when the preservation of the
spleen as an essential part of the developing immune sys-
tem appears to be of vital importance. The latter approach
is also indicated for hemangiomas partially located in the
splenic poles [3]. Embolization of hemangiomas, espe-
cially hepatic hemangiomas, has been shown to be as
effective as surgical removal and appears to be an appeal-
ing strategy taking into consideration the reported 2.4%
intra-operative mortality rate of hepatic resection. With
regard to splenic hemangioma embolization, a successful
partial embolization of the lower pole of the spleen has
been reported [11]. When radical surgery (splenectomy)
may prove risky because of other comorbidity we feel that
embolization of giant splenic hemangiomas may prove as
effective as in hepatic hemangiomas. It should to be noted
however that embolization is a minimally invasive tech-
nique which causes tumor infarction and necrosis, but
only occasionally reduction in tumor size [7]. Further-
more embolization of giant or multiple splenic hemangi-
omas may be used preoperatively as it appears to reduce
the risk of intra-operative hemorrhage [4,7,11]. In partic-
ular, in cases of synchronous presence of liver and spleen
hemangiomas, as in the case reported here, the combina-
tion of hepatic artery embolization and splenectomy may
be the optimal approach. We decided to undertake
splenectomy and observation for the small (<4 cm)
hepatic hemangiomas as suggested in the literature [1,3].
Caveats of embolization treatment of hemangiomas are
massive tumor necrosis with concomitant hepatic failure
(in the case of hepatic hemangiomas); postembolization
syndrome (abdominal pain, nausea, vomiting, and fever);
the possibility of a long-term revascularization (non radi-
cal intervention); and, in a number of cases, no regression
of tumor size [3,7,8]. Alternative therapies have been tried
including corticosteroids, anticoagulants, antiplatelets,
antifibrinolytics, interferon, radiation, or antiangiogenic
factors, especially in infants, with controversial results [3].
To our knowledge, there is no specific report of giant
splenic hemangiomas associated with administration of
oral contraceptives. There are numerous reports of intra-
hepatic and extrahepatic hemangiomas associated with
estrogen administration [2]. The exact incidence is
believed to be low. It is most common in women in their
late twenties who have been on oral contraceptives (OC)
for 7 years or more. Experimental studies have revealed
that estrogens augment endothelial cell proliferation,
migration and organization into capillary-like structures.
In vitro they also promote the proliferation of hemangi-
oma vascular endothelial cells and work synergistically
with vascular endothelial growth factor [12]. In another
study estrogen receptors were reported in hemangioma
tissue, an indication that hemangiomas may be target tis-
sues for estrogens [13]. On this pathophysiological basis
we may hypothesize a possible causative correlation
between OC and splenic hemangiomas along with
hepatic hemangiomas. Our patient had been taking oral
estrogens for many years, initially as treatment for infertil-
ity and subsequently because of an obscure chronic inter-
mittent pelvic pain. Another important observation by
Meyniel et al. is that OC administration increases heman-
gioma volume and favors rupture [2]. There are also
numerous reports on the absence of regression of heman-
giomas after OC discontinuation, as in our patient [14].
We feel that the synchronous manifestation of endometri-
osis and giant splenic hemangioma it is quite random,
although it should be noted.
Conclusion
Estrogen administration represents a predisposing factor
associated with the appearance of hemangiomas in solid
organs of the abdominal cavity. Giant splenic hemangi-
omas are extremely rare, and require surgical intervention
combined with observation or embolization of possibly
synchronous multiple small hepatic hemangiomas. Alter-
native approaches are preoperative embolization and sub-
sequent surgery, which minimizes the risk of intra-
operative bleeding, and partial splenectomy or emboliza-
tion in case of polar localization of small splenic heman-
giomas.
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